Next Article in Journal
Structures and Bioactive Properties of Myrtucommulones and Related Acylphloroglucinols from Myrtaceae
Next Article in Special Issue
Design and Synthesis of C-19 Isosteviol Derivatives as Potent and Highly Selective Antiproliferative Agents
Previous Article in Journal
Chemoinformatic Analysis of Selected Cacalolides from Psacalium decompositum (A. Gray) H. Rob. & Brettell and Psacalium peltatum (Kunth) Cass. and Their Effects on FcεRI-Dependent Degranulation in Mast Cells
Previous Article in Special Issue
Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma
Open AccessArticle

Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors

College of Pharmacy, Yanbian University, 977 Gongyuan Road, Yanji 133002, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Simona Collina and Mariarosaria Miloso
Molecules 2018, 23(12), 3369; https://doi.org/10.3390/molecules23123369
Received: 24 November 2018 / Revised: 13 December 2018 / Accepted: 17 December 2018 / Published: 19 December 2018
(This article belongs to the Special Issue Recent Advances in Anticancer Drugs)
The transforming growth factor-β (TGF-β), in which overexpression has been associated with various diseases, has become an attractive molecular target for the treatment of cancers. Thirty-two quinoxaline-derivatives of 3-substituted-4-(quinoxalin-6-yl) pyrazoles 14ad, 15ad, 16ad, 17ad, 18ad, 19ad, 25a, 25b, 25d, 26a, 26b, 26d, 27b, and 27d were synthesized and evaluated for their activin TGF-β type I receptor kinase and p38α mitogen activated protein (MAP) kinase inhibitory activity in enzymatic assays. Among these compounds, the most active compound 19b inhibited TGF-β type I receptor kinase phosphorylation with an IC50 value of 0.28 µM, with 98% inhibition at 10 µM. Compound 19b also had good selectivity index of >35 against p38α MAP kinase, with 9.0-fold more selective than clinical candidate, compound 3 (LY-2157299). A molecular docking study was performed to identify the mechanism of action of the synthesized compounds and their good binding interactions were observed. ADMET prediction of good active compounds showed that these ones possess good pharmacokinetics and drug-likeness behavior. View Full-Text
Keywords: TGF-β; ALK5 inhibitor; kinase assay; selectivity; docking TGF-β; ALK5 inhibitor; kinase assay; selectivity; docking
Show Figures

Graphical abstract

MDPI and ACS Style

Zhao, L.-M.; Guo, Z.; Xue, Y.-J.; Min, J.Z.; Zhu, W.-J.; Li, X.-Y.; Piao, H.-R.; Jin, C.H. Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors. Molecules 2018, 23, 3369.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop